Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.

ABSTRACT: GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.

PROVIDER: PRJNA832809 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18959200_1.fastq.gz	Fastqsanger.gz
	SRR18959200_2.fastq.gz	Fastqsanger.gz
	SRR18959201_1.fastq.gz	Fastqsanger.gz
	SRR18959201_2.fastq.gz	Fastqsanger.gz
	SRR18959202_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 100

Similar Datasets

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [ChIP-seq]

Project description:GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [ChIP-seq]

| PRJNA832810 | ENA

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [RNA-seq]

Project description:GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [RNA-seq]

| PRJNA832811 | ENA

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [ChIP-seq]

Project description:In order to identify GATA-3 target genes in T-cell lymphoproliferative neoplasms, we performed GATA-3 ChIP-seq on 3 cutaneous T-cell lymphoma (CTCL) and 4 T-cell acute lymphoblastic leukemia (T-ALL). We have also established cell lines in which GATA-3 was knocked down by shRNA.

2022-04-30 | GSE201743 | GEO

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [RNA-seq]

2022-04-30 | GSE201742 | GEO

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.

Project description:Neoplasms originating from thymic T-cell progenitors and post-thymic mature T-cell subsets account for a minority of lymphoproliferative neoplasms. These T-cell derived neoplasms, while molecularly and genetically heterogeneous, exploit transcription factors and signaling pathways that are critically important in normal T-cell biology, including those implicated in antigen-, costimulatory-, and cytokine-receptor signaling. The transcription factor GATA-3 regulates the growth and proliferation of both immature and mature T cells and has recently been implicated in T-cell neoplasms, including the most common mature T-cell lymphoma observed in much of the Western world. Here we show that GATA-3 is a proto-oncogene across the spectrum of T-cell neoplasms, including those derived from T-cell progenitors and their mature progeny, and further define the transcriptional programs that are GATA-3 dependent, which include therapeutically targetable gene products. The discovery that p300-dependent acetylation regulates GATA-3 mediated transcription by attenuating DNA binding has novel therapeutic implications. As most patients afflicted with GATA-3 driven T-cell neoplasms will succumb to their disease within a few years of diagnosis, these findings suggest opportunities to improve outcomes for these patients.

| S-EPMC9633835 | biostudies-literature

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-04-30 | GSE201744 | GEO

A Drosophila proto-oncogene homolog controls aggression via aminergic neurons

Project description:A Drosophila proto-oncogene homolog controls aggression via aminergic neurons

| PRJNA625242 | ENA

Muschampia proto

Project description:Muschampia proto overview

| PRJNA1182463 | ENA

The proto-oncogene TCL1A deregulates mitotic checkpoint transition and genomic stability in CLL

Project description:The proto-oncogene TCL1A deregulates mitotic checkpoint transition and genomic stability in CLL

| PRJNA791361 | ENA

The proto-oncogene TCL1A deregulates mitotic checkpoint transition and genomic stability in CLL

Project description:Upregulation of the proto-oncogene TCL1A is causally implicated in various B- and T-cell malignancies. High-level TCL1A correlates with aggressive disease features and inferior clinical outcomes. However, molecular and cell-biological consequences of TCL1A dysregulation are not fully elucidated. Here, we identify CDC20 and other molecules of the safeguarding cell cycle checkpoints as novel TCL1A-interactors. In different model systems of B-cell leukemia/lymphoma, TCL1A overexpression accelerated cell cycle transition, impaired apoptotic damage responses in association with pronounced chromosome mis-segregation and caused cellular aneuploidy. In primary CLL samples, low CDC20 expression correlated with high expression of TCL1A and more aggressive disease characteristics. In line, a low CDC20 expression was a marker for reduced progression-free survival in CLL patients. Finally, knockdown of CDC20 in TCL1A-initiated murine lymphomas promoted chromosome disbalances and leukemia outgrowth. Overall, we discovered a cell-cycle associated effect of TCL1A by interfering with a proficient cell cycle transition. This adds to our concept of TCL1A’s transforming impact by targeting genome stability.

2022-11-14 | PXD030776 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data